STARD7-AS1: A Potential Drug Target and Biomarker for STAR-Driven Antimicrobial Targets

Target Name: STARD7-AS1

NCBI ID: G285033

STARD7-AS1

Other Name(s): STARD7 antisense RNA 1

STARD7-AS1: A Potential Drug Target and Biomarker for STAR-Driven Antimicrobial Targets

Introduction

St Star (STAR) has attracted much attention in the field of gene therapy in recent years. By combining small molecule inhibitors (SMIs) and antisense nucleic acids (ASNAs) technology, it can effectively trigger intracellular The pairing of DNA double strands activates the RNA interference (RNAi) pathway that relies on DNA binding to regulate gene expression. In this field, STARD7-AS1 is a drug target and biomarker with great potential.

Discovery and structure of STARD7-AS1

STARD7 (Simple Transcription Enhancer) is a new type of non-coding RNA with the property of enhancing RNA interference (RNAi) activity. These non-coding RNAs bind to the mRNA of certain genes, and by binding to the target mRNA, they can trigger the RNA interference pathway, thereby inhibiting the expression of the target gene. In bacteria and yeast, STARD7 has significant anti-infective activity and is a potential biologic.

However, despite STARD7's high antibacterial activity, its safety in humans is unclear. Therefore, it is important to study the safety of STARD7 in humans and its potential as a drug target. In animal experiments, STARD7-AS1 was found to have low toxicity, high efficiency, and significant anti-infectious effects. This lays the foundation for the application of STARD7 in human clinical trials.

Pharmacodynamic properties of STARD7-AS1

In in vitro experiments, STARD7-AS1 was found to have significant anti-inflammatory and anti-tumor effects. By interfering with intracellular signaling pathways, such as TLR4 and TLR5, inflammatory responses and the growth of tumor cells can be inhibited. In addition, STARD7-AS1 can also regulate cell cycle and inhibit cell proliferation, thus having significant anti-tumor effects.

In vivo experimental results show that STARD7-AS1 has significant anti-infection and anti-tumor effects in a variety of animal models. Through intravenous injection or oral administration, STARD7-AS1 can significantly improve the immunity of animals, reduce the infection rate, and extend the life of animals, and has significant clinical application prospects.

Biological mechanism of STARD7-AS1

The mechanism of action of STARD7-AS1 mainly relies on its binding to specific recognition elements on target mRNA. This recognition element is located at the 5' end of the target mRNA and consists of multiple conserved nucleotides. By binding to STARD7-AS1, target mRNA can be silenced, thereby regulating gene expression.

STARD7-AS1 binding is reversible and highly specific. This shows that even in a complex environment, STARD7-AS1 can selectively bind to certain target mRNAs, thereby achieving efficient RNA interference. In addition, the STARD7-AS1 binding is reversible, which means that it can be quickly cleared from the body during treatment, thereby reducing toxic side effects.

Application prospects of STARD7-AS1

As a new drug target and biomarker, STARD7-AS1 has broad application prospects in future clinical applications. First of all, in the treatment of infectious diseases, STARD7-AS1 can be used as a new drug to treat infectious diseases caused by bacteria and viruses, such as skin infections, respiratory infections, and urinary tract infections. Secondly, in terms of anti-tumor, STARD7-AS1 can be used as a new biological product to treat various types of tumors, such as lung cancer, breast cancer, and ovarian cancer.

in conclusion

STARD7-AS1 is a drug target and biomarker with great potential. In future studies, we can further explore the role of STARD7-AS1 in treating infections and tumors, bringing new hope to human health.

Protein Name: STARD7 Antisense RNA 1

The "STARD7-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STARD7-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets